Milan, 23 June 2025 – MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a partnership with Negedia, an initiative born from Fondazione Telethon, aimed at expanding access to DNBSEQ™-powered genomic sequencing and Stereo-seq spatial transcriptomics for precision medicine and biomedical research in Italy. In the study of rare diseases and precision medicine, understanding gene expression within the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will enhance the biological and molecular understanding of various pathologies.
Negedia focuses on decoding individual genetic and molecular characteristics to enable informed decisions about prevention, wellness, and treatment. Serving researchers, specialists, and laboratories, it offers innovative solutions that deliver immediate insights for research and diagnostics.
Under this collaboration, MGI will supply advanced DNBSEQ™ sequencing technology to expand Negedia’s operational and analytical capacity. Negedia has acquired MGI’s DNBSEQ-T7 high-throughput sequencing platform, enabling high-resolution spatial transcriptomic analysis that captures the entire transcriptome—the RNA molecules transcribed from the genome—without compromising tissue integrity. This platform allows Negedia’s researchers to explore disease mechanisms at an unprecedented level, opening new avenues for discovery.
“At MGI, we believe cutting-edge technology is key to enhancing scientific research outcomes. That’s why we’re proud to collaborate with Negedia, equipping them with advanced sequencing tools to help push the boundaries of science. In rare disease research and precision medicine, understanding gene expression in the spatial context of tissues has been a major challenge. Thanks to our technology, we can now overcome this hurdle, providing Negedia scientists with new ways to deepen biological and molecular insights into various diseases,” said Dr. Christian Zimmerman, Vice President of Sales, Europe and Africa at MGI.
STOmics’ proprietary Stereo-seq (SpaTial Enhanced REsolution Omics-sequencing) technology, distributed by MGI, is revolutionizing spatial multi-omics for scientific research and clinical applications. These include oncology—studying tumour microenvironments and cellular interactions within neoplastic tissues; neuroscience—mapping cellular organization in brain tissues and investigating neurodegenerative diseases; developmental biology and embryology—tracking spatiotemporal gene expression during tissue and organ formation; and precision medicine—identifying new biomarkers for diagnostics and targeted therapies.
Negedia is a Certified Service Provider for Stereo-seq technology, having completed rigorous certification to ensure the highest standards of quality and reliability. This process included establishing dedicated laboratories with specialized instruments for STOmics protocols, advanced team training in cryosectioning and sample preparation, and optimization of procedures to deliver consistent, reproducible results.
“Negedia is excited to begin this collaboration with STOmics and to integrate their Spatial Transcriptomics technology into our research toolbox. This completely unbiased methodology opens new doors for discovery and exploratory analysis,” stated Prof. Davide Cacchiarelli, Chief Scientific Officer at Negedia.
Spatial transcriptomic analysis is made possible by Stereo-seq technology, developed by STOmics and implemented via MGI’s DNBSEQ-T7 platform. Stereo-seq offers nanometre-scale resolution and a centimetre-level field of view (up to 13cm x 13cm), far exceeding the detail achievable with standard single-cell analysis. Samples can be examined not only at the cellular level but also within individual cells and even smaller structures.
At the heart of Stereo-seq is its innovative chip design—a silicon chip featuring millions of microscopically and geographically localized points, allowing researchers to precisely locate the origin of specific mRNA molecules. Stereo-seq has the potential to revolutionize our understanding of tissue organization, disease mechanisms, and drug responses by revealing gene expression patterns at an unprecedented spatial resolution.
Thanks to this technology, researchers can generate higher-quality data compared to conventional methods, driving significant advances in precision medicine research to benefit patients.
This collaboration marks a major step forward in advancing precision medicine and rare disease research in Italy by empowering scientists with tools to analyse gene expression in the spatial context of tissues—a crucial dimension for understanding complex biological processes and disease mechanisms. Expanding access to advanced genetic sequencing enables more accurate diagnoses and personalized treatments based on each patient’s genetic profile. Beyond improving clinical outcomes, this fosters a more preventive, data-driven, and efficient healthcare approach that could transform medical practice nationwide.
About NEGEDIA
Negedia is an advanced genomics service laboratory supporting biomedical research through next-generation sequencing (NGS) and multi-omics technologies. Founded with the scientific support of Fondazione Telethon, Negedia delivers high-quality, ready-to-publish data to accelerate discovery in genetics, transcriptomics, and spatial biology.
Its services include bulk and single-cell RNA sequencing, spatial transcriptomics, digital gene expression profiling, and whole genome sequencing—all optimized for complex and clinically relevant samples. As a certified provider for leading platforms, Negedia ensures technical excellence, reproducibility, and scientific reliability throughout the workflow.
Based in Pozzuoli (Naples, Italy), Negedia collaborates with academic institutions, research hospitals, and biotech companies to advance life sciences innovation.
Learn more at negedia or follow on LinkedIn.
Watch the full video here.
